Genus comes in on track
Genus, the global animal genetics company, said its full year figures would be in line with expectations after a good performance over the last two months.
Genus, the global animal genetics company, said its full year figures would be in line with expectations after a good performance over the last two months.
The company said pricing had remained firm, with adjusted operating profit improving in line with expectations despite increasing investment in research and growing its management teams.
Profits had improved strongly in Asia, particularly in Russia and China, and in Latin America, it said.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Going forward, the firm expects strong growth in emerging markets, particularly in China.
The group's businesses in North America also performed well due to cost controls and improved royalty income offsetting softness there.
Europe had performed broadly in line with the prior year, it added.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Rents rise at slowest pace for four years – is buy-to-let still worth it?
Slowing rental growth and higher property taxes are creating a headache for landlords. Does buy-to-let still offer a good yield?
-
Should you bag a bargain with a half-price investment trust?
Twenty-six investment trusts look cheap by historic standards, with some trading at a discount of more than 50%. Are they a bargain or value trap?